Tiziana Life Sciences LTD (TLSA) SEC Filings — 2025
42 SEC filings for Tiziana Life Sciences LTD (TLSA) in 2025.
Filings
- Tiziana Life Sciences Submits 7th Annual Safety Report to FDA — 6-K · Dec 29, 2025
- Tiziana Life Sciences LTD 6-K Filing — 6-K · Dec 19, 2025
- Tiziana Life Sciences Doses First Patient in Alzheimer's Trial — 6-K · Dec 17, 2025
- Tiziana Life Sciences Withdraws Public Offering — 6-K · Dec 15, 2025
- Tiziana Life Sciences LTD 6-K Filing — 6-K · Dec 12, 2025
- Tiziana Life Sciences LTD 6-K Filing — 6-K · Dec 2, 2025
- Tiziana Life Sciences' ALS Trial Joins MyMatch Program — 6-K · Nov 25, 2025
- Tiziana Life Sciences to Present at Jefferies London Healthcare Conference — 6-K · Nov 13, 2025
- Tiziana Life Sciences to Present at BIO-Europe 2025 — 6-K · Oct 29, 2025
- Tiziana Life Sciences Reports Interim Financials & Program Update — 6-K · Oct 3, 2025
- Tiziana Life Sciences Invited to J.P. Morgan Life Science Forum — 6-K · Sep 30, 2025
- Tiziana Life Sciences Advances Anti-IL-6R Antibody TZLS-501 — 6-K · Sep 25, 2025
- Tiziana Life Sciences to Present at ECTRIMS Congress — 6-K · Sep 24, 2025
- Tiziana Life Sciences Secures DoD Grant for Spinal Cord Injury Therapy — 6-K · Sep 15, 2025
- Tiziana Life Sciences CEO Buys Shares — 6-K · Sep 9, 2025
- Tiziana Life Sciences Chairman Buys Shares — 6-K · Sep 5, 2025
- Tiziana Life Sciences Doses First Patient in MSA Trial — 6-K · Aug 14, 2025
- Tiziana Life Sciences FDA Approves IND for MSA Trial — 6-K · Aug 11, 2025
- Tiziana Life Sciences Reports Alzheimer's Treatment Findings — 6-K · Jul 21, 2025
- Tiziana Life Sciences CEO to Present Clinical Findings at Bio Convention — 6-K · Jun 13, 2025
- Tiziana Life Sciences Alzheimer's Nasal Spray Featured on NPR — 6-K · May 23, 2025
- Tiziana Life Sciences Study Shows Foralumab Dampens Microglial Activation — 6-K · May 15, 2025
- Tiziana Life Sciences Founder Buys Shares — 6-K · May 12, 2025
- Tiziana Life Sciences Reports Alzheimer's Treatment Success — 6-K · May 9, 2025
- Tiziana Life Sciences Files 20-F/A Amendment — 20-F/A · May 8, 2025
- Tiziana Life Sciences Files 2024 Annual Report — 20-F · May 6, 2025
- Tiziana Life Sciences Starts Dosing at Fourth Site for MS Trial — 6-K · Apr 23, 2025
- Tiziana Life Sciences Doses Patients in SPMS Trial at Johns Hopkins — 6-K · Apr 2, 2025
- Tiziana Life Sciences Doses New Patients in MS Trial — 6-K · Mar 25, 2025
- Tiziana Life Sciences CEO to Speak at ROTH Conference — 6-K · Mar 17, 2025
- Tiziana Life Sciences Regains Nasdaq Listing Compliance — 6-K · Mar 14, 2025
- Tiziana Life Sciences Files IND for ALS Phase 2 Trial — 6-K · Mar 4, 2025
- Tiziana Life Sciences Study Shows Nasal Antibody Reduces Neuroinflammation — 6-K · Feb 27, 2025
- Tiziana Life Sciences' Foralumab Shows Promise for Long COVID — 6-K · Feb 25, 2025
- Tiziana Life Sciences Partners with Renaissance for Nasal Drug Delivery — 6-K · Feb 21, 2025
- Tiziana Life Sciences Doses More MS Patients in Expanded Access Program — 6-K · Feb 18, 2025
- Tiziana Life Sciences Drug Featured on News Channel — 6-K · Feb 11, 2025
- Tiziana Life Sciences Faces Nasdaq Delisting Warning — 6-K · Jan 31, 2025
- Tiziana Life Sciences Reports SCI Study Results — 6-K · Jan 24, 2025
- Tiziana Life Sciences Discovers New MS Biomarkers — 6-K · Jan 22, 2025
- Tiziana Life Sciences: Nasal Antibody Shows Prolonged Benefits — 6-K · Jan 10, 2025
- Tiziana Life Sciences' Foralumab Highlighted in Nature Reviews Neurology — 6-K · Jan 8, 2025